Rigel Pharmaceuticals
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Rigel Pharmaceuticals generated cash of -$5,743,000, which is more than the previous year. Cash used in financing activities reached the amount of $18,367,000 last year. Net change in cash is therefore $8,327,000.
Cash Flow
| 2014 | -69.75M | 62.93M | 1.17M |
|---|---|---|---|
| 2015 | -23.41M | 44.61M | 7.05M |
| 2016 | -75.88M | 24.88M | 25.18M |
| 2017 | -77.55M | -19.47M | 117.68M |
| 2018 | -58.82M | 24.96M | 71.89M |
| 2019 | -41.51M | -23.65M | 11.36M |
| 2020 | -52.18M | 47.46M | 12.57M |
| 2021 | 5.87M | -80.03M | 62.67M |
| 2022 | -73.75M | 72.77M | 6.55M |
| 2023 | -5.74M | -4.29M | 18.36M |
RIGL Cash Flow Statement (2014 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 24.45M | 18.89M | 30.37M | 22.52M | 76.32M | 38.29M | 17.63M | 43.45M | 15.20M | 20.85M |
Operating activities | ||||||||||
Net income | -25.09M | -58.57M | -17.91M | -29.74M | -66.89M | -70.48M | -77.99M | -69.21M | -51.46M | -90.90M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||||
Depreciation and amortization | 1.23M | 998K | 1.16M | 706K | 683K | 594K | 465K | 941K | 1.43M | 2.35M |
Stock-based compensation expense | 8.80M | 12.38M | 9.48M | 7.29M | 9.11M | 0 | 5.98M | 7.33M | 7.40M | 9.78M |
| Deferred income tax benefit | 8.80M | 12.38M | 9.48M | 7.29M | 9.11M | 0 | 5.98M | 7.33M | 7.40M | 9.78M |
| Changes in operating assets and liabilities: | ||||||||||
Accounts receivable, net | 9.77M | -24.84M | 501K | -5.86M | -6.03M | -4.07M | 0 | 203K | 5.54M | 0 |
Inventories | 1.17M | -2.37M | -4.87M | -126K | -366K | -839K | 0 | 2.09M | 801K | 0 |
Accounts payable | -366K | 3.78M | 41K | -331K | -2.23M | 3.75M | -2.94M | 2.8M | 1.15M | -2.29M |
Cash generated by operating activities | -5.74M | -73.75M | 5.87M | -52.18M | -41.51M | -58.82M | -77.55M | -75.88M | -23.41M | -69.75M |
Investing activities | ||||||||||
Purchases Of Investments | -31.20M | -28.89M | -141.45M | -81.70M | -145.32M | -77.99M | -116.86M | -103.05M | -151.76M | -218.59M |
Investments In Property Plant And Equipment | 0 | -450K | -627K | -1.26M | -1.45M | -1.10M | -164K | -804K | -546K | -413K |
Acquisitions Net | 0 | 893K | 627K | 1.26M | 1.45M | 1.10M | 732K | 88K | 60K | 0 |
Cash generated by investing activities | -4.29M | 72.77M | -80.03M | 47.46M | -23.65M | 24.96M | -19.47M | 24.88M | 44.61M | 62.93M |
Financing activities | ||||||||||
Common Stock Issued | 1.04M | 2.12M | 4.77M | 2.59M | 1.57M | 0 | 114.18M | 23.58M | 5.29M | 1.17M |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repayments of term debt | 19.95M | 4.42M | -57.9M | -9.97M | 0 | 0 | 0 | 0 | 0 | 0 |
Cash used in financing activities | 18.36M | 6.55M | 62.67M | 12.57M | 11.36M | 71.89M | 117.68M | 25.18M | 7.05M | 1.17M |
Net Change In Cash | 8.32M | 5.56M | -11.48M | 7.85M | -53.80M | 38.03M | 20.65M | -25.82M | 28.25M | -5.65M |
Cash at end of period | 32.78M | 24.45M | 18.89M | 30.37M | 22.52M | 76.32M | 38.29M | 17.63M | 43.45M | 15.20M |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source |